The World Health Organization (WHO) recently called on countries to prioritise recognition, rehabilitation and research for the consequences of Covid-19, and the collection of standardised data on Long Covid. They proposed the term “Post Covid-19 Condition” should be used for people living with Long Covid.
A significant portion of people diagnosed with Covid-19 subsequently experience lasting symptoms including fatigue, breathlessness and neurological complications months after the acute infection. However, the evidence for this condition is limited and based on small patient cohorts with short-term follow-up.
Core outcome set
There is an urgent need for the development of a core outcome set (COS) to optimise and standardise clinical data collection and reporting across studies (especially clinical trials) and clinical practice for this condition. With this in mind, clinical research communities and people living with Post Covid-19 Condition have come together to respond to this emerging global healthcare crisis.
An international group of experts in COS development and Post Covid-19 Condition research and clinical practice have developed a programme of research together with WHO, ISARIC (International Severe Acute Respiratory and emerging Infection Consortium), and patient partners to develop a Post Covid-19 Condition COS.
People living with Post-Covid-19 Condition
This project, Post-Covid Condition Core Outcomes, will start by surveying people living with Post-Covid-19 Condition, assess what outcomes matter and build a plan in two phases. The first phase will focus on what outcomes should be measured and the second phase will focus on how to measure these outcomes.
Researchers aim to complete the first phase (what outcomes to measure) in the summer of 2021 and the second phase (how to measure these outcomes) in 2022.
This project follows the COMET (Core Outcome Measures in Effectiveness Trials) Initiative’s standards and has been registered on COMET’s COS registry.
This plan is being globally publicised in its early stages so that research and patient communities are aware, thereby potentially avoiding any unnecessary duplication of work, and to let researchers planning studies, especially clinical trials, and clinicians know the anticipated time frame of these recommendations.